Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APIXA-Xa: Variability of Anti-Xa Activity of Apixaban vs Rivaroxaban in NVAF
NCT06862726Phase 4Enrolling by invitation
- Sponsor
- Les Laboratoires des Médicaments Stériles
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of apixaban, rivaroxaban in nonvalvular atrial fibrillation (NVAF), sponsored by Les Laboratoires des Médicaments Stériles. Started Dec 2024; status: enrolling by invitation.
02
Drugs
apixabanrivaroxaban
03
Conditions
nonvalvular atrial fibrillation (NVAF)
Beyond the preview
Go deeper on NCT06862726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06862726.